Via Pharmaceuticals Inc · OTC:VIAP
Via Pharmaceuticals — Investor Presentation (May 2008)
30 slides from Via Pharmaceuticals's investor presentation, May 14, 2008
Slide 1: Investor Presentation May, 2008
Investor Presentation May, 2008
Slide 2: Safe Harbor
3 SAFE HARBOR This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that
Slide 3: VIA Investment Highlights
5 VIA Investment Highlights Inflammation -- root cause of cardiovascular disease resulting in heart attack and stroke Lead compound, VIA-2291 has best-in-class potential Comprehensive Phase 2 program to show proof-of-concept with data beginning in Q3 2008 Potent, oral, once-daily compound inhibits k
Slide 4: Significant Recent Developments
7 Significant Recent Developments Solid clinical trial experience Positive safety and efficacy data from DSMB Launch of innovative FDG PET Phase 2 trial Hire of Dr. Rebecca Taub as Sr. VP - R&D Expansion of Clinical Advisory Board
Slide 5: VIA-2291 Late Stage Clinical Development Plan
5 2006 2007 2008 2009 VIA-2291 Phase 2 Program Carotid Endarterectomy (CEA) Acute Coronary Syndrome (ACS) FDG PET VIA-2291 Late Stage Clinical Development Plan Phase 2 Proof of Concept Program designed to provide weight of evidence pointing to efficacy
Slide 6: Inflammation Matters in Cardiovascular Disease
11 Inflammation Matters in Cardiovascular Disease
Slide 7: Large Market with Significant Unmet Medical Need
13 Large Market with Significant Unmet Medical Need 30.3 million patients in US and Europe and 2.7 million at "high risk" following ACS events Current therapies treat only risk factors Cardiovascular spend in 7 major World Markets >$115 billion in 2006 Source: Data Monitor 2007 $28.7 B $20.8 B $16.1
Slide 8: Available Therapies Only Reduce MACE by ~30%
15 Available Therapies ONLY Reduce MACE by 20 - 30% IDEAL Prove IT HPS 4S LIPID CARE CAPRIE Reduction in MACE 0.11 0.16 0.24 0.32 0.25 0.23 19 Risk not addressed 0.88000000026296 0.83000000013148 0.75 0.67 0.74 0.76 81 Lipitor Zocor Pravachol Published Results Plavix
Slide 9: Inflammation is Key to All Stages of CV Disease
17 Inflammation is Key to All Stages of CV Disease Early stages of atherosclerosis Inflammatory process Early atherosclerotic lesions Vulnerable plaque Stable plaque Healthy artery MACE Plaque rupture is a cause of Major Adverse Cardiovascular Events
Slide 10: Lead Compound VIA-2291 in Late Stage Phase 2 Program
19 Lead Compound VIA-2291 in comprehensive late stage Phase 2 clinical trial program
Slide 11: Leukotrienes Mediate Vascular Inflammation
Leukotrienes Mediate Vascular Inflammation 5-LO is the rate limiting enzyme LTB4 recruits and activates inflammatory cells in unstable plaque 5LO is a validated pharmaceutical target VIA identified 5-LO as target for atherosclerosis Human genetic data implicates 5-LO in MACE Expression data in mouse
Slide 12: VIA-2291: Significantly De-risked Product
23 VIA-2291: Significantly De-risked Product Second generation 5-LO Inhibitor Strong product characteristics Once daily oral dosing Highly specific Potential for greater therapeutic index Extensive clinical experience - more than 1,100 patients exposed 20 Phase 1 studies, 6 Phase 2 studies, 2 Phase
Slide 13: Significant Human Data on VIA-2291
25 Significant Human Data on VIA-2291 VIA-2291 Dose versus % LTB4 Inhibition Human data from Abbott showing the effective inhibition of LTB4 at multiple doses
Slide 14: Phase 3 Trials Drive Novel Phase 2 Program
27 Phase 3 in secondary prevention will be an outcomes trial Phase 2 program needs to demonstrate proof-of-concept Integration of histology, imaging and biomarker endpoints Demonstrate direct impact on disease process State of the art design - FDA "Critical Path" initiative Phase 3 Trials Drive Nove
Slide 15: Phase 2 Trial - Carotid Endarterectomy (CEA)
29 Phase 2 Trial - Carotid Endarterectomy (CEA) Trial Design Population Carotid artery disease Carotid Endarterectomy Description 50 patients enrolled Randomized, double-blind 3 months 100mg/day or placebo pre-surgery Endpoints Inhibition of 5-LO Inflammatory biomarkers Plaque inflammation and histo
Slide 16: Phase 2 Trial - Acute Coronary Syndrome (ACS)
31 Phase 2 Trial - Acute Coronary Syndrome (ACS) Trial Design Population Coronary artery disease Acute Coronary Syndrome Description 200 patients within 21 days of heart attack Randomized, double-blind 3 months 25mg/day, 50mg/day,100 mg/day or placebo Endpoints Inhibition of 5-LO Inflammatory biomar
Slide 17: Phase 2 Trial - FDG PET
33 Phase 2 Trial - FDG PET Tahara, et al 2006 Trial Design Population Coronary artery disease Acute Coronary Syndrome Description 50 patients within 1 - 3 months of an ACS event Randomized, double-blind 24 weeks, 100 mg/day or placebo Positron Emission Tomography with fluorodeoxyglucose tracer (FDG
Slide 18: Innovative, Comprehensive Clinical Strategy
CEA ACS FDG-PET Focus on secondary prevention patients with safety and dose- ranging info Utilizing leading edge technology to demonstrate impact on inflammation Creating strong weight of evidence Unique access to diseased plaque tissue Innovative, Comprehensive Clinical Strategy Raising the Bar for
Slide 19: Broad Pipeline
Broad Pipeline . VIA
Slide 20: Broad Development Pipeline
39 Broad Development Pipeline Compound/Target Area of Focus Research Pre-Clinical Phase 1 Phase 2 Phase 3 VIA-2291 / 5-LO Carotid Endarterectomy Acute Coronary Syndrome FDG PET LTA4 Hydrolase Vascular Inflammation PDE 4 Vascular Inflammation
Slide 21: VIA Proprietary Technology Platform
41 VIA Proprietary Technology Platform 4 year, $30 million study at Stanford headed by VIA Founder/CSO Inflammation key in human atherosclerosis Extensive data from work in mouse model confirms human findings >3,000 patient study confirms inflammatory genes in heart attack and stroke Database for pr
Slide 22: Broad Pool of Anti Inflammatory Compounds
43 Broad Pool of Anti Inflammatory Compounds Qualified Targets Anti inflammatory Compounds Identified Opportunities Preclinical Clinical Stage LOs (5-LO, 12-LO, FLAP) 189 109 75 34 Leukotrienes (LTA4, LTB4, LTC4, LTD4 189 189 135 54 PPARs (^,^,^) 99 92 52 40 PDEs (mostly PDE4) 153 153 95 58 Chemokin
Slide 23: Data Shows 35% Reduction in Vascular Inflammation
45 Data Shows 35% Reduction in Vascular Inflammation * * Reduction in mouse model plaque macrophage with VIA-2291 * p < 0.05 Vessel wall macrophage density 70 60 50 40 30 20 10 0 0.9% Saline VIA-2291, 10mg/kg VIA-2291, 50mg/kg
Slide 24: Significant Progress
Significant Progress Py VIA
Slide 25: 2007 Accomplishments & Upcoming Milestones
2007 Accomplishments & Upcoming Milestones 2007 - 2008 Accomplishments Launched VIA Pharmaceuticals as public company Raised $25 million in PIPE financing Initiated PDE4 and LTA4 preclinical programs DSMB review confirmed safety and pharmacological effect Initiated FDG-PET Phase 2 Formed expanded cl
Slide 26: Experienced Management Team
Personnel Position Experience Larry Cohen, PhD CEO Zyomyx, Progenitor, Somatix, Therion Oye Olukotun, MD, MPH CMO Bristol-Myers Squibb, Mallinckrodt, Esperion Tom Quertermous, MD CSO Dept Cardiovascular Medicine, Stanford Medical School Mike Perry, DVM, PhD CDO Baxter, Novartis, Schering-Plough Jim
Slide 27: World Class Advisors
World Class Advisors Scientific Advisory Board Israel Charo, MD, PhD UCSF Christopher Glass, MD, PhD UCSD Colin Funk, PhD Queens University Garret FitzGerald, MD University of Pennsylvania Marco Conti, MD Stanford Medical School Todd Klingler, PhD XDx, Inc. Clinical Advisory Board Marc Pfeffer, MD,
Slide 28: Financial Update
55 Financial Update Cash balance - approximately $17.9 million at March 31, 2008 Cash burn - approximately $2.0 - 2.1 million / month Total common shares outstanding 19.7 million Fully diluted shares outstanding 23.7 million
Slide 29: VIA Investment Highlights
57 VIA Investment Highlights Inflammation -- root cause of cardiovascular disease resulting in heart attack and stroke Lead product candidate, VIA-2291 has best-in-class potential Lead compound has strong value proposition Building pipeline utilizing proprietary technology platform licensed from Sta
Slide 30: VIA Pharmaceuticals
—— VIA pharmaceuticals VIA
VIA Pharmaceuticals — Investor Presentation (May 2008) on 6ix